| Darian Vincent Minkunas, MD | |
|
10163 Se Sunnyside Rd Ste 490, Clackamas, OR 97015-5720 | |
| (503) 513-4400 | |
| Not Available |
| Full Name | Darian Vincent Minkunas |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 29 Years |
| Location | 10163 Se Sunnyside Rd Ste 490, Clackamas, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467534909 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00035809 (Washington) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD20560 (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of The Northwest | 5799688230 | 1482 |
News Archive
The development of graphene-a highly advanced metamaterial with many unique and varied properties-may lead to exciting new applications in the diagnosis and treatment of neurological diseases, according to a report in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.
CryoPort, Inc. today announced it has closed a private placement with various accredited investors for gross proceeds of $5.0 million. The Company obtained agreements to purchase 9,119,100 shares of common stock at $0.55 per share.
› Verified 9 days ago
| Entity Name | Kaiser Foundation Health Plan Of The Northwest |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184786527 PECOS PAC ID: 5799688230 Enrollment ID: O20040130000799 |
News Archive
The development of graphene-a highly advanced metamaterial with many unique and varied properties-may lead to exciting new applications in the diagnosis and treatment of neurological diseases, according to a report in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.
CryoPort, Inc. today announced it has closed a private placement with various accredited investors for gross proceeds of $5.0 million. The Company obtained agreements to purchase 9,119,100 shares of common stock at $0.55 per share.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Darian Vincent Minkunas, MD 10163 Se Sunnyside Rd, Suite 490, Clackamas, OR 97015-5743 Ph: (503) 513-4400 | Darian Vincent Minkunas, MD 10163 Se Sunnyside Rd Ste 490, Clackamas, OR 97015-5720 Ph: (503) 513-4400 |
News Archive
The development of graphene-a highly advanced metamaterial with many unique and varied properties-may lead to exciting new applications in the diagnosis and treatment of neurological diseases, according to a report in the May issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company's Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.
Five years ago, large numbers of farmers in central China began falling victim to an mysterious disease marked by high fever, gastrointestinal disorder and an appalling mortality rate - as high as 30 percent in initial reports. Investigators from the Chinese Center for Disease Control and Prevention hurried to the scene of the outbreak. On the basis of DNA evidence, they quickly concluded that it had been caused by human granulocytic anaplasmosis, a bacteria transmitted by tick bites.
CryoPort, Inc. today announced it has closed a private placement with various accredited investors for gross proceeds of $5.0 million. The Company obtained agreements to purchase 9,119,100 shares of common stock at $0.55 per share.
› Verified 9 days ago
Dr. Cara Lee Rozell, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 10180 Se Sunnyside Rd, Dept Of Neurology, Clinic C, Clackamas, OR 97015 Phone: 503-571-7200 | |
Cheryl Ann Chessick, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 10163 Se Sunnyside Rd, Ste. 490, Clackamas, OR 97015 Phone: 503-249-3434 | |
Dr. Heather Lynn Knott, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 12901 Se 97th Ave Ste 105, Clackamas, OR 97015 Phone: 503-912-4788 Fax: 503-912-4787 | |
Dr. Han-chun Liang, M.D., M.B.A. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 10163 Se Sunnyside Rd Ste 490, Clackamas, OR 97015 Phone: 503-249-3434 | |
Dr. Rory E. Green, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 10163 Se Sunnyside Rd, Suite 490, Clackamas, OR 97015 Phone: 503-513-4400 | |
Dr. Christina E Peterson, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 15259 Se 82nd Dr, 201b, Clackamas, OR 97015 Phone: 503-656-9844 Fax: 503-656-3120 | |
My Chuong, Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 9800 Se Sunnyside Rd, Clackamas, OR 97015 Phone: 800-813-2000 |